Adicet Bio rises as cancer therapy shows promise in pre-clinical study

ADICET Bio

18/05/2023 13:06

** Shares of drug developer Adicet Bio Inc  ACET.O  rise 3%
to $6.87 premarket
    ** Co's anti-cancer therapy ADI-270 shows significant
inhibition of tumor growth in pre-clinical study in cancers with
CD70 expression
    ** CD70 target molecule is expressed in many cancer types
including renal, lung and blood cancers
    ** ADI-270 also shows improved resistance against rejection
by patient's immune system - ACET
    ** Stock down ~25.4% YTD as of last close

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))